Robe of Cyclin D1 as a Mediator of c-Met- and β-Catenin-Induced Hepatocarcinogenesis

被引:72
作者
Patil, Mohini A. [1 ,2 ]
Lee, Susie A. [1 ]
Macias, Everardo [4 ]
Lam, Ernest T. [1 ]
Xu, Chuanrui [1 ,5 ]
Jones, Kirk D. [3 ]
Ho, Coral [1 ]
Rodriguez-Puebla, Marcelo [4 ]
Chen, Xin [1 ,2 ]
机构
[1] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[4] N Carolina State Univ, Dept Mol Biomed Sci, Raleigh, NC 27695 USA
[5] Huazhong Univ Sci & Technol, Union Hosp, Ctr Stem Cell Res & Applicat, Wuhan, Peoples R China
关键词
HUMAN HEPATOCELLULAR CARCINOMAS; PROTEIN-COUPLED RECEPTOR; SKIN TUMOR-DEVELOPMENT; TRANSGENIC MICE; GROWTH-FACTOR; LIVER-CANCER; IN-VIVO; HA-RAS; EXPRESSION; BREAST;
D O I
10.1158/0008-5472.CAN-08-2514
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activation of c-Met signaling and P-catenin mutations are frequent genetic events observed in liver cancer development. Recently, we demonstrated that activated beta-catenin can cooperate with c-Met to induce liver cancer formation in it mouse model. Cyclin DI (CCND1) is an important cell cycle regulator that is considered to be a downstream target of beta-catenin. To determine the importance of CCND1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis, we investigated the genetic interactions between CCND1, beta-catenin, and c-Met in liver cancer development using mouse models. We coexpressed CCND1 with c-Met in mice and found CCND1 to cooperate with c-Met to promote liver cancer formation. Tumors induced by CCND1 /c-Met had a longer latency period, formed at a lower frequency, and seemed to be more benign compared with those induced by beta-catenin/c-Met. In addition, when activated beta-catenin and c-Met were coinjected into CCND1-null mice, liver tumors developed despite the absence of CCND1. Intriguingly, we observed a moderate accelerated tumor growth and increased tumor malignancy in these CCND1-null mice. Molecular analysis showed an up-regulation of cyclin D2 (CCND2) expression in CCND1-null tumor samples, indicating that CCND2 may replace CCND1 in hepatic tumorigenesis. Together, our results suggest that CCND1 functions as a mediator of P-catenin during HCC pathogenesis, although other molecules may be required to fully propagate beta-catenin signaling. Moreover, our data suggest that CCND1 expression is not essential for liver tumor development induced by c-Met and beta-catenin. [,Cancer Res 2009;69(1):253-61]
引用
收藏
页码:253 / 261
页数:9
相关论文
共 49 条
[1]   Identification of stem cells in small intestine and colon by marker gene Lgr5 [J].
Barker, Nick ;
van Es, Johan H. ;
Kuipers, Jeroen ;
Kujala, Pekka ;
van den Born, Maaike ;
Cozijnsen, Miranda ;
Haegebarth, Andrea ;
Korving, Jeroen ;
Begthel, Harry ;
Peters, Peter J. ;
Clevers, Hans .
NATURE, 2007, 449 (7165) :1003-U1
[2]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[3]  
Cadigan Ken M., 2002, Trends in Genetics, V18, P340, DOI 10.1016/S0168-9525(02)02707-5
[4]  
Cadoret A, 2001, CANCER RES, V61, P3245
[5]   Disruption of β-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice [J].
Calvisi, DF ;
Factor, VM ;
Ladu, S ;
Conner, EA ;
Thorgeirsson, SS .
GASTROENTEROLOGY, 2004, 126 (05) :1374-1386
[6]   Wnt/β-catenin signaling in development and disease [J].
Clevers, Hans .
CELL, 2006, 127 (03) :469-480
[7]   Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads to hepatocellular carcinomas [J].
Colnot, S ;
Decaens, T ;
Niwa-Kawakita, M ;
Godard, C ;
Hamard, G ;
Kahn, A ;
Giovannini, M ;
Perret, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (49) :17216-17221
[8]   Enhanced tumor formation in cyclin D1 x transforming growth factor β1 double transgenic mice with characterization by magnetic resonance imaging [J].
Deane, NG ;
Lee, H ;
Hamaamen, J ;
Ruley, A ;
Washington, MK ;
LaFleur, B ;
Thorgeirsson, SS ;
Price, R ;
Beauchamp, RD .
CANCER RESEARCH, 2004, 64 (04) :1315-1322
[9]  
Deane NG, 2001, CANCER RES, V61, P5389
[10]   Hepatocellular carcinoma - An epidemiologic view [J].
El-Serag, HB .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 35 (05) :S72-S78